TRCT
IBIO icon

Tower Research Capital (TRC)’s iBio IBIO Stock Holding History

Tower Research Capital (TRC)’s Portfolio IBIO Stock Details IBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,380
Closed -$2.66K – 5304
2025
Q4 		$2.66K Sell
1,380
-353
-20% -$482 ﹤0.01% 4488
2025
Q3 		$1.44K Sell
1,733
-374
-18% -$287 ﹤0.01% 4787
2025
Q2 		$1.61K Buy
2,107
+2,089
+11,606% +$2.27K ﹤0.01% 4778
2025
Q1 		$72 Sell
18
-1,603
-99% -$6.23K ﹤0.01% 5059
2024
Q4 		$3.97K Sell
1,621
-583
-26% -$1.5K ﹤0.01% 4558
2024
Q3 		$4.89K Sell
2,204
-1,157
-34% -$2.29K ﹤0.01% 4385
2024
Q2 		$7.09K Sell
3,361
-2,242
-40% -$4.82K ﹤0.01% 4499
2024
Q1 		$22.7K Buy
5,603
+820
+17% +$1.03K ﹤0.01% 2883
2023
Q4 		$6.55K Buy
4,783
+4,778
+95,560% +$20.9K ﹤0.01% 4726
2023
Q3 		$30 Hold
5
– – ﹤0.01% 5812
2023
Q2 		$61 Sell
5
-10
-67% -$189 ﹤0.01% 5857
2023
Q1 		$1K Buy
15
+10
+200% +$257 ﹤0.01% 5554
2022
Q4 		$0 Buy
+5
New +$169 ﹤0.01% 6115
2022
Q3 		– Sell
-26
Closed -$3K – 6249
2022
Q2 		$3K Sell
26
-25
-49% -$3.76K ﹤0.01% 5381
2022
Q1 		$11K Buy
51
+18
+55% +$3.77K ﹤0.01% 4175
2021
Q4 		$9K Buy
33
+21
+175% +$8.01K ﹤0.01% 4697
2021
Q3 		$6K Sell
12
-18
-60% -$11.2K ﹤0.01% 4751
2021
Q2 		$22K Sell
30
-36
-55% -$26.3K ﹤0.01% 3804
2021
Q1 		$51K Sell
66
-5
-7% -$4.36K ﹤0.01% 3109
2020
Q4 		$37K Sell
71
-31
-30% -$25.3K ﹤0.01% 3393
2020
Q3 		$104K Buy
102
+97
+1,940% +$141K ﹤0.01% 3117
2020
Q2 		$5K Buy
+5
New +$3.27K ﹤0.01% 4273
2016
Q1 		– Hold
0
– -$1K – 4485
2015
Q4 		– Hold
0
– – – 4088
2015
Q3 		– Hold
0
– – – 3622
2015
Q2 		– Sell
-1
Closed -$4.65K – 3733
2015
Q1 		$3K Sell
1
-1
-50% -$3.39K ﹤0.01% 3566
2014
Q4 		$9K Buy
+2
New +$10.7K ﹤0.01% 2230

Other funds holding IBIO

AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Tower Research Capital (TRC)'s IBIO Position: Q1 2026 in Review

Tower Research Capital (TRC) sold out of iBio (IBIO) in Q1 2026, closing a stake of 1,380 shares — an estimated $2.66K sold.

Tower Research Capital (TRC) first reported a position in IBIO in Q4 2014 and held it in 24 quarters. The position peaked at $104K in Q3 2020. 52 funds tracked by Wall St. Rank hold IBIO as of Q1 2026.

  • Tower Research Capital (TRC) reported no remaining iBio position as of Q1 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 1,380 iBio shares in Q1 2026, an estimated $2.66K.
  • Tower Research Capital (TRC) first reported a position in iBio in Q4 2014 and held it in 24 quarters.
  • Tower Research Capital (TRC)'s iBio position peaked at $104K in Q3 2020.
  • 52 funds tracked by Wall St. Rank held iBio as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.